《新股消息》(方土方)博醫療(02216.HK)公開發售超購10倍及上限定價 一手中籤率僅6.58%
專注於介入呼吸病學產品開發的(方土方)博醫療(02216.HK)公佈招股結果,以招股價上限18.7元定價,料淨集資約15.52億元,本港公開發售部分錄得超額認購約10.13倍,國際配售部分亦已獲適度超額認購。每手500股計,一手中籤率爲6.58%。該股將於明日(24日)掛牌。高盛、海通爲聯席保薦人。
公司獲10名基石投資者當中包括UBS AM Singapore、Lake Bleu Prime、雪湖資本等,已認購合共3,781.9萬股發售股份,佔緊隨全球發售完成後公司已發行股本的約7.2%。
公司擬將所得款項淨額約49.9%用予研發其核心產品;約18.5%用予研發其他產品及候選產品;約9.2%爲繼續擴大其生產廠房的生產線提供資金;約13.2%將用於通過潛在收購持續擴大產品組合提供資金;約9.2%用於營運資金及其他一般公司用途。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.